A High-Throughput Behavioral Assay for Screening Novel Anxiolytics in Larval Zebrafish

Area of Science:

• Neuroscience
• Pharmacology
• Behavioral Science

Background:

• Anxiety disorders impact millions globally, necessitating novel treatments due to current therapy limitations.
• Existing small molecule discovery methods lack high-throughput vertebrate anxiety assays.
• Larval zebrafish dark avoidance models anxiety-like behavior and responds to anxiolytics.

Purpose of the Study:

• To develop and validate a high-throughput assay for discovering novel anxiolytic compounds.
• To assess the utility of larval zebrafish dark avoidance in a 96-well plate format.
• To identify potential new anxiolytic candidates.

Main Methods:

• Characterization of larval zebrafish with strong dark avoidance (SDA) as a model for pathological anxiety.
• Development of a high-throughput 96-well plate behavioral assay for dark avoidance.
• Testing known anxiolytics (Chlordiazepoxide, Buspirone) and a novel compound (AS1) for efficacy.

Main Results:

• The 96-well assay reliably detected anxiolytic effects of Chlordiazepoxide and Buspirone.
• The assay demonstrated sensitivity to the novel compound AS1, reducing dark avoidance.
• The platform's validity and sensitivity for anxiolytic screening were established.

Conclusions:

• The dark avoidance assay is scalable to a 96-well format for high-throughput screening.
• This assay provides a robust platform for discovering novel anxiolytic compounds.
• This research facilitates the development of new treatments for anxiety disorders.